Entero Healthcare Share Price: Q3 mein kamaal! Revenue **25%**, EBITDA **35%** bhaga!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Entero Healthcare Share Price: Q3 mein kamaal! Revenue **25%**, EBITDA **35%** bhaga!
Overview

Entero Healthcare ke liye Q3 FY26 ek dum zabardast raha! Company ka revenue **25.6%** badh kar **₹1,706.5 Cr** ho gaya aur EBITDA bhi **35.5%** chadh kar **₹67.8 Cr** tak pahunch gaya. Ye sab MedTech segment mein bade acquisitions aur margin expansion ki wajah se hua hai.

Aao dekhte hain Entero Healthcare ke Q3 FY26 ke results, aur bhai, numbers ekdum solid hain! Company ka consolidated revenue 25.6% jump kar ke ₹1,706.5 Crore ho gaya hai. Sirf revenue hi nahi, EBITDA toh 35.5% tez hua hai, jo ₹67.8 Crore bana hai. Gross Profit bhi 29.4% badh kar ₹172.6 Crore ho gaya, aur Gross Margins bhi 30 bps sudhar kar 10.1% ho gaye hain. Ye sab margin expansion aur strategic acquisitions ki wajah se ho raha hai, khaas kar MedTech segment mein. EBITDA Margins bhi 29 bps badh kar 4.0% ho gaye hain. Agar 9 Mahine (9MFY26) ki baat karein, toh EBITDA 46.7% badha hai aur margins 58 bps sudhre hain. Reported PAT mein 8.6% ka jump hai, jo ₹27.6 Crore hai, lekin agar exceptional items hatayein toh PAT before exceptional items 35.8% badh kar ₹40.0 Crore ho gaya. Woh ₹8.2 Crore ka exceptional item New Labour Code ke impact ki wajah se tha.

Sabse mast baat yeh hai ki company ne operating cash flow mein ek zabardast turnaround dikhaya hai! Jaha pehle negative tha, wahi ab ₹49 Crore generate kiye hain Q3 mein. Working Capital days bhi ab 64 days par hain. Profitability ratios bhi sudhre hain, ROCE 14.8% ho gaya hai aur ROE bhi 12.3% tak aa gaya hai.

CEO Prabhat Agrawal ne kaha ki is quarter mein 17.1% ka organic growth rate raha hai, jo kaafi achha hai. Aur company ne deal pe deal ki hai! Q3 FY26 mein aur uske baad 4 bade acquisitions finish kiye hain – Anand Medilink Pvt. Ltd., Ace Cardiopathy Solutions Pvt. Ltd., Bioaide Technologies Pvt. Ltd., aur Anand Chemiceutics. Ye sab MedTech segment ko strong karne ke liye kiye gaye hain, aur company expect kar rahi hai ki FY27 tak MedTech revenue ₹1,000 Crore cross kar jayega. Focus IVD, Cardiology, aur Orthopedic devices par hai.

Is acquisitions ke khel ne balance sheet mein bhi changes laye hain. Goodwill ₹192.8 Crore (March 2024) se badh kar ₹424.0 Crore (March 2025) ho gaya hai. Total borrowings thoda badh kar ₹298.8 Crore tak pahunchi hain, lekin Debt-to-Equity ratio abhi bhi maintain hai, lagbhag 0.17 par.

Abhi ek chhota sa risk bhi aaya hai ki unki subsidiary, Atreja Healthcare Solutions, ka drug license teen din ke liye suspend hua tha kuch violations ki wajah se, jisse ₹1.88 million ka potential revenue loss ho sakta tha. Company ka kehna hai ki isse overall operations par koi bada impact nahi pada hai. Investors ko ab dhyan rakhna hoga ki ye sab acquired companies properly integrate ho paati hain ya nahi, margins badhte rehte hain ya nahi, aur cash flow positive bana rehta hai ya nahi. Overall, company apni growth story ko aage badhane ke liye ready lag rahi hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.